Goldman Sachs
HEPA

Goldman Sachs’s Hepion Pharmaceuticals HEPA Stock Holding History

Goldman Sachs’s Portfolio HEPA Stock Details HEPA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-15
Closed -$19K – 6558
2022
Q1 		$19K Sell
15
-20
-57% -$22.1K ﹤0.01% 6417
2021
Q4 		$40K Buy
35
+23
+192% +$31.5K ﹤0.01% 6298
2021
Q3 		$18K Sell
12
-56
-82% -$89.7K ﹤0.01% 6156
2021
Q2 		$135K Buy
+68
New +$124K ﹤0.01% 5871
2017
Q2 		– Hold
0
– -$23K – 6839
2017
Q1 		– Hold
0
– – – 6479
2016
Q4 		– Hold
0
– – – 6643
2016
Q2 		– Hold
0
– -$14K – 7112
2016
Q1 		– Hold
0
– – – 6830

Other funds holding HEPA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
ML
McAdam LLC Philadelphia, Pennsylvania $2.22B AUM 16.98% 1-Year Est. Return

Goldman Sachs's HEPA Position: Q2 2022 in Review

Goldman Sachs sold out of Hepion Pharmaceuticals (HEPA) in Q2 2022, closing a stake of 15 shares — an estimated $19K sold.

Goldman Sachs first reported a position in HEPA in Q2 2021 and held it in 4 quarters. The position peaked at $135K in Q2 2021. 28 funds tracked by Wall St. Rank hold HEPA as of Q2 2022.

  • Goldman Sachs reported no remaining Hepion Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Goldman Sachs sold 15 Hepion Pharmaceuticals shares in Q2 2022, an estimated $19K.
  • Goldman Sachs first reported a position in Hepion Pharmaceuticals in Q2 2021 and held it in 4 quarters.
  • Goldman Sachs's Hepion Pharmaceuticals position peaked at $135K in Q2 2021.
  • 28 funds tracked by Wall St. Rank held Hepion Pharmaceuticals as of Q2 2022.

Based on Goldman Sachs's 13F filing for Q2 2022, filed 15 Aug 2022.